Viral vectors are critical components in the manufacturing of cell and gene therapies, but their production is currently a key bottleneck and cost driver. CCRM, a company that develops and commercializes cell and gene therapies, has partnered with Membio, a Canadian biotechnology company developing a 0.2-10 L benchtop single-use bioreactor system, to streamline production of viral vectors. This will be the first collaboration of the two organizations and will explore combining Membio’s bioreacto...